Halozyme to Present at Upcoming Investor Conferences
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences.
2024年11月27日，聖地亞哥/PRNewswire/--Halozyme Therapeutics，Inc.（納斯達克: HALO）（"Halozyme"）今日宣佈，執行領導團隊成員計劃在以下投資者會議上進行演講並舉辦投資者會議。
Details on the presentations are as follows:
演示的詳細信息如下:
|
Event: |
Piper Sandler 36th Annual Healthcare Conference |
|||
|
Presenter: |
Nicole LaBrosse, Chief Financial Officer |
|||
|
Format: |
Fireside Chat and 1x1 Meetings |
|||
|
Presentation Date: |
Wednesday, December 4, 2024 |
|||
|
Presentation Time: |
10:30am PT / 1:30pm ET |
|||
|
Location: |
New York, NY |
|
Event: |
派傑投資第36屆醫療保健年會 |
|||
|
報告人： |
Nicole LaBrosse, 首席財務官 |
|||
|
格式： |
零星對話和一對一會議 |
|||
|
演講日期： |
2024年12月4日星期三 |
|||
|
演講時間： |
上午10:30 Pt / 下午1:30 ET |
|||
|
地點： |
關於Veeva Systems |
|
Event: |
7th Annual Evercore ISI HealthCONx Conference |
|||
|
Presenter: |
Helen Torley, President and Chief Executive Officer |
|||
|
Format: |
Fireside Chat and 1x1 Meetings |
|||
|
Presentation Date: |
Wednesday, December 4, 2024 |
|||
|
Presentation Time: |
9:30am PT / 12:30pm ET |
|||
|
Location: |
Miami, FL |
|
Event: |
第7屆Evercore ISI HealthCONx會議 |
|||
|
報告人： |
Helen Torley，總裁兼首席執行官 |
|||
|
格式： |
零星對話和一對一會議 |
|||
|
演講日期： |
2024年12月4日星期三 |
|||
|
演講時間： |
9:30上午太平洋時間 / 12:30下午東部時間 |
|||
|
地點： |
邁阿密，FL |
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
公司網站的投資者關係板塊將提供演示的現場音頻網絡廣播。會後的音頻網絡廣播可在會議後的90天內提供回放。
About Halozyme
Halozyme是一家生物製藥公司，致力於提高新興和成熟治療方案的患者體驗和結果，推進顛覆性的解決方案。作爲ENHANZE藥物輸送技術的創新者，擁有專有酶rHuPH20，Halozyme的商業驗證解決方案用於促進注射藥物和流體的皮下給藥，旨在減輕患者的治療負擔。Halozyme在100多個全球市場的七個商業化產品中接觸了超過80萬個患者生命，在後市場使用中得到證明。Halozyme已將其ENHANZE技術授權給領先的製藥和生物技術公司，包括羅氏，武田，輝瑞，Janssen，艾伯維，伊利莎和施貴寶、argenx，ViiV Healthcare，中外製藥和Acumen Pharmaceuticals。
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme是一家生物製藥公司，致力於改善新興和成熟療法的患者體驗和治療結果。作爲ENHANZE藥物遞送技術的創新者，Halozyme的商業化驗證解決方案用於促進通過皮下注射遞送藥物和液體，旨在改善通過快速皮下遞送和減少治療負擔來提高患者體驗。Halozyme已在100多個全球市場上通過8種商業化產品影響了80多萬患者，已將其ENHANZE技術授權給包括Roche、武田、輝瑞、詹森、艾伯維、伊利莎白・利莉、施貴寶、argenx、威瑞夫保健、千代製藥和Acumen Pharmaceuticals在內的領先製藥和生物技術公司。
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme也開發、製造並商業化先進的自動注射器技術，用於自身或與合作伙伴合作，生產藥物-器械組合產品。這些產品旨在提供商業或功能上的優勢，如改進的便利性、可靠性和耐受性，以及增強患者舒適度和依從性。公司擁有兩款商業專有產品Hylenex和XYOSTED，合作的商業產品以及與Teva Pharmaceuticals和Idorsia Pharmaceuticals的持續產品開發計劃。
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
有關更多信息，請訪問網站並在LinkedIn和Twitter上與我們聯繫。
For more information visit and connect with us on LinkedIn and Twitter.
欲獲取更多信息請訪問並關注我們的LinkedIn和Twitter
Contacts:
聯繫人：
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
Tram Bui
副總裁，投資者關係和企業溝通
609-359-3016
[email protected]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
薩曼莎 加斯帕
Teneo
212-886-9356
[email protected]
SOURCE Halozyme Therapeutics, Inc.
源自Halozyme Therapeutics, Inc。
